Acta Neuropathologica Communications (Jan 2021)

The App NL-G-F mouse retina is a site for preclinical Alzheimer’s disease diagnosis and research

  • Marjan Vandenabeele,
  • Lien Veys,
  • Sophie Lemmens,
  • Xavier Hadoux,
  • Géraldine Gelders,
  • Luca Masin,
  • Lutgarde Serneels,
  • Jan Theunis,
  • Takashi Saito,
  • Takaomi C. Saido,
  • Murali Jayapala,
  • Patrick De Boever,
  • Bart De Strooper,
  • Ingeborg Stalmans,
  • Peter van Wijngaarden,
  • Lieve Moons,
  • Lies De Groef

DOI
https://doi.org/10.1186/s40478-020-01102-5
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 16

Abstract

Read online

Abstract In this study, we report the results of a comprehensive phenotyping of the retina of the App NL-G-F mouse. We demonstrate that soluble Aβ accumulation is present in the retina of these mice early in life and progresses to Aβ plaque formation by midlife. This rising Aβ burden coincides with local microglia reactivity, astrogliosis, and abnormalities in retinal vein morphology. Electrophysiological recordings revealed signs of neuronal dysfunction yet no overt neurodegeneration was observed and visual performance outcomes were unaffected in the App NL-G-F mouse. Furthermore, we show that hyperspectral imaging can be used to quantify retinal Aβ, underscoring its potential as a biomarker for AD diagnosis and monitoring. These findings suggest that the App NL-G-F retina mimics the early, preclinical stages of AD, and, together with retinal imaging techniques, offers unique opportunities for drug discovery and fundamental research into preclinical AD.

Keywords